No Ginger in Ginger Ale – “Nuisance Litigation” Against Food Manufacturers Continues to Rise

Posted by Crista Trippodi Murphy on Posted on

On July 10, 2018, a federal lawsuit was filed contending that Canada Dry and its parent company Dr. Pepper Snapple, Inc. misled customers by falsely advertising “Made from Real Ginger”. This suit is the latest among several brought against the company asserting that customers believed Canada Dry Ginger Ale to have health benefits because it
Read More

New Jersey Adopts Stricter Standards for Admissibility of Expert Testimony

Posted by Crista Trippodi Murphy on Posted on

On August 1, 2018, the New Jersey State Supreme Court handed down a landmark decision when they unanimously voted to adopt stricter standards for expert testimony, affirming the court’s role as the “gatekeeper of scientific evidence”. Expert Testimony Properly Excluded The court’s ruling is a direct result of ongoing litigation surrounding claims that the prescription
Read More

Biosimilar Patent Litigators Can Benefit from the Right Consulting and Testifying Experts

Posted by Crista Trippodi Murphy on Posted on

The commercialization of biosimilars was enabled by the Biologics Price Competition and Innovation Act (BPCIA) of 2009 which was signed into law on March 22, 2010 as part of the Patient Protection and Affordable Care Act. Biologics are produced using living organisms, and thus, are usually much more complex than most small molecule drugs. Biosimilars
Read More

The Importance of Genetics Experts in Pharmaceutical Litigation

Posted by Crista Trippodi Murphy on Posted on

A Case Study from the Testosterone Litigation A recent defense verdict in the testosterone litigation highlights the importance of genetics in pharmaceutical litigation. In this case, neither the plaintiffs nor the defense called a geneticist as an expert, yet both sides tried to use genetic arguments in their case. In this post we summarize the
Read More

Protein-based adverse drug reactions (ADRs): Using proteomics to assess drug safety

Posted by Crista Trippodi Murphy on Posted on

Each year, adverse drug events cost millions of dollars in hospital admissions, injuries to patients, and malpractice. And companies spend billions of dollars on litigation involving allegations that their drugs caused adverse drug reactions (ADRs). What if there was a better way to determine individualized drug adverse events? Welcome to the Age of Proteomics The
Read More

Human-Organs-on-Chips: Will They Revolutionize Courtroom Toxicology Testimony?

Posted by Crista Trippodi Murphy on Posted on

Human-Organs-on-Chips are microfluidic cell culture microchips lined with living human cells that simulate the functions of human organs, including the lung, intestine, kidney, skin, bone marrow and blood-brain barrier. Engineered by Dr. Donald Ingber and Wyss Institute researchers in 2010, these microchips have the potential to revolutionize drug development, disease modeling, and personalized medicine. But
Read More

Toxicology in the 21st Century – 5 Tips for Litigators

Posted by Crista Trippodi Murphy on Posted on

Chemicals are part of everyday life. They are found in common household and workplace products including food, packaging, paint and dyes, cleaning supplies, medicines, among many other categories of products. Yet, only a small number of chemicals have been thoroughly assessed for their potential toxicity in humans. Furthermore, there are an increasing number of commercially
Read More